BioXcel Therapeutics (BioXcel Therapeutics) Total Liabilities : $130.21 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Total Liabilities?

BioXcel Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $130.21 Mil.

BioXcel Therapeutics's quarterly Total Liabilities increased from Jun. 2023 ($134.23 Mil) to Sep. 2023 ($141.06 Mil) but then declined from Sep. 2023 ($141.06 Mil) to Dec. 2023 ($130.21 Mil).

BioXcel Therapeutics's annual Total Liabilities increased from Dec. 2021 ($17.77 Mil) to Dec. 2022 ($129.08 Mil) and increased from Dec. 2022 ($129.08 Mil) to Dec. 2023 ($130.21 Mil).

BioXcel Therapeutics Total Liabilities Historical Data

The historical data trend for BioXcel Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Total Liabilities Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

9.50

13.24

17.77

129.08

130.21

BioXcel Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															129.08	127.10	134.23	141.06	130.21

BioXcel Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioXcel Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27.267	+	(101.038	+	1.905
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	130.21

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	73.702	-	-56.508
	=	130.21

BioXcel Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27.267	+	(101.038	+	1.905
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	130.21

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	73.702	-	-56.508
	=	130.21

BioXcel Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (BioXcel Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Executives

Vimal Mehta	director, officer: CEO, President, Secretary	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Richard I Steinhart	officer: Chief Financial Officer	125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez	officer: SEE REMARKS	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Krishnan Nandabalan	director, 10 percent owner	228 VILLAGE POND ROAD, GUILFORD CT 06437
Akrati Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello	10 percent owner	10 TEMPLETON ROAD, WALLINGFORD CT 06492
Krunal Dilip Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Alka Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Pardeep Kumar Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Anita Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437